Zydus Lifesciences secures USFDA okay for angina drug Isosorbide Mononitrate ER
Ahmedabad: Pharma major Zydus Lifesciences Limited has announced that the Company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg (USRLD: Imdur Extended-Release Tablets).
Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease).
The product will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.
Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg had annual sales of USD 47 mn in the United States (IQVIA Dec. Nov. 2023). The group now has 388 approvals and has so far filed over 460* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Lifesciences gets tentative USFDA approval for Dexamethasone Tablets USP, 1 mg
Formerly known as Cadila Healthcare Limited, Zydus Lifesciences Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the production of generic drugs. Cadila was founded in 1952 by Ramanbhai Patel.
Read also: Zydus Lifesciences gets tentative USFDA approval for Dexamethasone Tablets USP, 1 mg
